Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study - Université de Lorraine Access content directly
Journal Articles Clinical Gastroenterology and Hepatology Year : 2022

Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study

1 Hôpital Nord [CHU - APHM]
2 NGERE - Nutrition-Génétique et Exposition aux Risques Environnementaux
3 Service d'Hépato-gastro-entérologie [CHRU Nancy]
4 Hôpital Beaujon [AP-HP]
5 CHU Saint-Antoine [AP-HP]
6 SU - Sorbonne Université
7 AP-HP - Hopital Saint-Louis [AP-HP]
8 EC2M3 - Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375)
9 Groupe Henri Mondor-Albert Chenevier
10 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
11 CHRU Montpellier - Hôpital Saint Eloi
12 Hôpital Haut-Lévêque [CHU Bordeaux]
13 UB - Université de Bordeaux
14 Hôpital Cochin [AP-HP]
15 UPD5 - Université Paris Descartes - Paris 5
16 USPC - Université Sorbonne Paris Cité
17 CHU - Hôpital Archet 2 [Nice]
18 Hôpital de Bayonne [Bayonne]
19 INFINITE - Institute for Translational Research in Inflammation - U 1286
20 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
21 CIRI - Centre International de Recherche en Infectiologie
22 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
23 CHU Caen
24 CHU-Liège - Centre Hospitalier Universitaire de Liège
25 CHD Vendée - Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon
26 CHU Nîmes - Centre Hospitalier Universitaire de Nîmes
27 M2iSH - Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte
28 CHU Clermont-Ferrand
29 Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
30 CHRU Tours - Centre Hospitalier Régional Universitaire de Tours
31 CHIC - Centre Hospitalier Intercommunal de Créteil
32 Centre Hospitalier Henri Duffaut (Avignon)
33 Service des Maladies Infectieuses et Tropicales [CHRU Nancy]
34 UL - Université de Lorraine
35 MPI - Département Méthodologie Promotion Investigation [CHRU Nancy]
36 MEPHI - Microbes évolution phylogénie et infections
37 APHM - Assistance Publique - Hôpitaux de Marseille
38 AMU - Aix Marseille Université
Stéphanie Viennot
  • Function : Author


Background and aims: Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), and human immunodeficiency virus (HIV) both impact innate and adaptive immunity in the intestinal mucosa. As it is a rare situation, the intersection between HIV and IBD remains unclear, especially the impact of HIV infection on the course of IBD, and the drug safety profile is unknown.Methods: We conducted a multicenter retrospective cohort study between January 2019 and August 2020. All adult patients with IBD and concomitant HIV infection were included. Each IBD patient with HIV was matched to two HIV-uninfected IBD patients.Results: Overall, 195 patients with IBD were included, including 65 HIV-infected patients and 130 without HIV infection. Of the 65 infected patients, 22 (33.8%) required immunosuppressants and 31 (47.7%) biologics. In the HIV-infected group, the need for immunosuppressants (p = 0.034 for CD and p = 0.012 for UC) and biologics (p = 0.004 for CD and p = 0.008 for UC) was significantly lower. The disease course, using a severity composite criterion, was not significantly different between the two groups for CD (hazard ration (HR) = 1.3 [0.7; 2.4], p = 0.45) and UC (HR, 1.1 [0.5; 2.7], p = 0.767). The overall drug safety profile was statistically similar between the two groups.Conclusion: Although HIV-infected patients receive less treatments, the course of their IBD did not differ than uninfected, suggesting that HIV infection might attenuate IBD. The drug safety profile is reassuring, allowing physician to treat these patients according to current recommendations.
Fichier principal
Vignette du fichier
S1542356520317195.pdf (707.2 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-04168380 , version 1 (22-07-2024)




Lucas Guillo, Mathieu Uzzan, Laurent Beaugerie, Jean-Marc Gornet, Aurélien Amiot, et al.. Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study. Clinical Gastroenterology and Hepatology, 2022, 20 (4), pp.787-797.e2. ⟨10.1016/j.cgh.2020.12.023⟩. ⟨hal-04168380⟩
61 View
0 Download



Gmail Mastodon Facebook X LinkedIn More